The U.S. FDA has issued an emergency safety alert regarding the use of inhalation anesthetics, including sevoflurane, following reports of severe neurological complications and fatalities. This action was prompted by clinical reports indicating that these anesthetics, previously considered safe, can cause unexpected and severe brain damage in specific patient populations. Notably, both adult and pediatric patients have exhibited severe neurological adverse effects, such as permanent basal ganglia degeneration, shocking the medical community. This situation highlights a significant public health crisis, necessitating a comprehensive re-evaluation of the safety profiles of marketed drugs.

Investigations have revealed a strong association between these adverse effects and the 'MT-ND4 m.11232T>C' mitochondrial gene mutation, which is primarily found in individuals of Venezuelan descent. This genetic mutation inhibits the activity of Complex I in the mitochondrial electron transport chain, disrupting cellular energy production. Inhalation anesthetics typically target and inhibit Complex I; therefore, in genetically predisposed individuals exposed to these anesthetics, this can lead to severe energy depletion and cell death. This clinical case underscores the importance of pharmacogenomics, demonstrating how a patient's genetic factors can determine their response to drugs.

Healthcare professionals should exercise extreme caution when using inhalation anesthetics in patients with Venezuelan ancestry, regardless of family history, as the mitochondrial DNA (mtDNA) is maternally inherited, and individuals may carry the mutation even without a prior history of anesthetic adverse events. Consequently, the FDA and the American Society of Anesthesiologists (ASA) recommend prioritizing the use of intravenous anesthetics, such as propofol, or regional anesthesia when clinically appropriate, as alternatives to inhalation anesthetics. In emergency situations where genetic screening is not feasible, the active implementation of these alternative anesthetic protocols is crucial for ensuring patient safety.

The recent increase in international humanitarian medical support in areas near Venezuela, following the recent earthquake, makes this warning particularly relevant. If aid organizations and medical personnel continue to use standard anesthesia practices when performing surgeries on local residents, it could lead to a large-scale adverse event. Therefore, global pharmaceutical companies and non-governmental organizations (NGOs) that provide medical supplies should immediately revise local anesthesia safety manuals and proactively secure alternative medications. This goes beyond a simple drug warning and has the potential to change the standard guidelines for global health security and humanitarian aid.

This incident demonstrates that even drugs that have been widely used for decades can exhibit fatal toxicity in specific populations. Manufacturers of sevoflurane, such as AbbVie's Ultane and Baxter's generic versions, are now obligated to promptly modify product labels and gather additional safety data. This clearly indicates that regulatory agencies' post-market surveillance systems must evolve to incorporate precision medicine technologies. Companies should support the development of diagnostic technologies that can proactively identify at-risk patient populations, thereby mitigating long-term legal risks and regulatory uncertainties.